IFIH1 and clinically amyopathic dermatomyositis: Anti-MDA5 antibody-positive (MDA5+) DM is usually classified as CADM, which is mainly characterized by rapid progressive pulmonary interstitial disease, acute respiratory distress syndrome, and resistance to conventional treatments, resulting in a high mortality rate (2).